glp 1 trump administration Novo Nordisk, Lilly strike deal with to slash weight-loss drug prices Trump administration makes deal to

The scientists compared people who got GLP-1 drugs for their diabetes with people who got drugs that use a different mechanism to control blood sugar levels

BioRender ( was used to create the Fig

The Unbundled Model: Lower advertised medication price, but services billed separately

Novo nordisk files for regulatory approval of once-weekly semaglutide with the fda for the treatment of type 2 diabetes

We cant put someone on GLP-1s for only two years and expect them to maintain, Thiara says

Pauling This Pharmacology Consult will focus on GLP-1 receptor agonists that are currently FDA approved for weight loss, including semaglutide (Wegovy, Novo Nordisk) and liraglutide (Saxenda, Novo Nordisk), but other FDA-approved options exist, such as orlistat, naltrexone/bupropion and phentermine/topiramate